Soleus Capital Management LP recently announced the acquisition of new stake in Organogenesis Holdings Inc (NASDAQ:ORGO). The institutional investor has increased its shareholding in the Healthcare company by 4.84% to 12.3 million shares with purchase of 0.57 million shares. This fresh investment now brings its stake to 9.31% valued currently at $31.36 million. In addition, Morgan Stanley & Co. LLC raised its holdings by 6.0 million to 6.84 million shares. And BlackRock Fund Advisors has lifted its position by 1.22% or 52333.0 shares – to 4.34 million shares.
With over 0.48 million Organogenesis Holdings Inc (ORGO) shares trading Friday and a closing price of $3.96 on the day, the dollar volume was approximately $1.89 million. The shares have shown a positive half year performance of 17.16% and its price on 12/22/23 gained nearly 2.06%. Currently, there are 130.92M common shares owned by the public and among those 78.79M shares have been available to trade.
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 2 analysts who have offered their price forecasts for ORGO have a consensus price objective of $3.75. The analysts have set the share’s price value over the next 12 months at a high of $4.00 and a low of $3.50. The average price target is -5.6% below its recent price level and a downside to the estimated low will see the stock lose -13.14% over that period. But an upside of 1.0% will see the stock hit the forecast high price target while median target price for the stock is $3.75.
Insiders at the company have transacted a total of 31 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 12 of these insider trades were purchases, accounting for 2,530,051 shares. Insider sales of the common stock occurred on 19 occasions, with total insider shares sold totaling 111,801 shares.
The top 3 mutual fund holders in Organogenesis Holdings Inc are Vanguard Total Stock Market ETF, iShares Russell 2000 ETF, and Xtrackers SICAV – S&P 500 2x Leve. Vanguard Total Stock Market ETF owns 1.88 million shares of the company’s stock, all valued at over $4.8 million. iShares Russell 2000 ETF bought 861.0 shares to see its total holdings expand to 1.75 million shares valued at over $4.46 million and representing 1.33% of the shares outstanding. Xtrackers SICAV – S&P 500 2x Leve now owns shares totaling to 1.13% of the shares outstanding.
However, the script later moved the day high at 4.0400, up 2.06%. The company’s stock has a 5-day price change of 5.60% and 59.68% over the past three months. ORGO shares are trading 47.21% year to date (YTD), with the 12-month market performance up to 51.72% higher. It has a 12-month low price of $1.79 and touched a high of $4.50 over the same period. ORGO has an average intraday trading volume of 961.06K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 25.14%, 48.41%, and 37.87% respectively.
Institutional ownership of Organogenesis Holdings Inc (NASDAQ: ORGO) shares accounts for 39.64% of the company’s 130.92M shares outstanding. Mutual fund holders own 27.88%, while other institutional holders and individual stakeholders account for 60.26% and 11.78% respectively.
It has a market capitalization of $522.88M. The stock’s trailing 12-month PE ratio is 40.49, while the earnings-per-share (ttm) stands at $0.10. The company has a PEG of 16.80 and a Quick Ratio of 2.43 with the debt-to-equity ratio at 0.44. Price movements for the stock have been influenced by the stock’s volatility, which stands at 5.42% over the week and 6.85% over the month.
Analysts forecast that Organogenesis Holdings Inc (ORGO) will achieve an EPS of $Perrigo Company plc for the current quarter, $31.70 for the next quarter and $Stocks for Type. The lowest estimate earnings-per-share for the quarter is $Organogenesis Holdings Inc. while analysts give the company a high EPS estimate of $Orgenesis Inc.. Comparatively, EPS for the current quarter was $BERGIO INTL INC a year ago. Earnings per share for the fiscal year are expected to decrease by -66.22%, and 17.99% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 2 brokerage firm advisors rate Organogenesis Holdings Inc (ORGO) as a “Moderate Buy” at a consensus score of 2.00. Specifically, 1 Wall Street analysts polled rate the stock as a buy, while 1 of the 2 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the ORGO, a number of firms have released research notes about the stock. Morgan Stanley stated their Equal-Weight rating for the stock in a research note on June 15, 2023, with the firm’s price target at $5.
